secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001493152-23-006284
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma receives Nasdaq deficiency notice for bid price below $1.00 per share
--------------------------------------------------------------------------------

- Received Nasdaq deficiency letter on Feb 22, 2023; stock closed below $1.00 for 30 consecutive business days.
- Has 180 calendar days, until August 21, 2023, to regain compliance by closing at $1.00+ for 10 consecutive business days.
- May qualify for a second 180-day period if it meets other listing standards and provides written notice.
- Company intends to monitor bid price and consider available options to cure the deficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315223006284/0001493152-23-006284-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315223006284/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-006284

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer